Understand the source comparison
Peptides for Inflammation: Mechanism Comparison
BPC-157 VEGF receptor modulation, growth factor upregulation IL-6 ↓ 62%, TNF-α ↓ 58% Tendon injury, gastric ulceration, wound healing Strongest evidence for localised tissue repair; requires subcutaneous administration near injury site for maximal effect KPV N
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF receptor modulation, growth factor upregulation
- IL-6 ↓ 62%, TNF-α ↓ 58%
- Tendon injury, gastric ulceration, wound healing
- Strongest evidence for localised tissue repair; requires subcutaneous administration near injury site for maximal effect
- KPV
- NF-κB nuclear translocation inhibition
- IL-8 ↓ 54%, IL-1β ↓ 48%
- Inflammatory bowel disease, skin inflammation
- Tripeptide structure allows oral administration with mucosal absorption; particularly effective for GI-targeted research
- Thymosin Beta-4
- IL-10 upregulation, cytokine balance shift
- IL-1β ↓ 47%, IL-10 ↑ 39%
- Cardiac inflammation, corneal injury, systemic inflammation
- Accelerates inflammatory resolution phase rather than blocking acute response; 43-residue length requires careful storage
- Thymalin
- T-regulatory cell modulation, thymic peptide complex
- Anti-inflammatory cytokine profile shift
- Autoimmune conditions, immune senescence
- Thymic extract requires consistent sourcing; effect size correlates with baseline Treg dysfunction severity
- LL-37
- Cathelicidin-derived, NF-κB inhibition + antimicrobial
- TNF-α ↓ 51%, maintains phagocytic function
- Sepsis models, wound infection with inflammation
- Dual anti-inflammatory and antimicrobial activity; particularly relevant for infection-inflammation overlap research